Bloomberg Law
April 13, 2022, 9:35 AM

Medicare’s Alzheimer’s Drug Plan Falls Short on Diversity Access

Celine Castronuovo
Celine Castronuovo

Racial minorities and others disproportionately affected by Alzheimer’s disease could continue facing barriers to treatment unless Medicare does more to facilitate access to research and safety studies, policy watchers say.

The Centers for Medicare & Medicaid Services’ finalized plan for Biogen Inc.’s Aduhelm restricts coverage to patients enrolled in certain clinical trials. The agency says approved studies must include a diverse group of patients representative of the national diagnosed population. But patient advocates say it doesn’t clarify how trial organizers can combat geographic, financial, and safety barriers to participation.

These vulnerable patients are “the ones that are going to ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.